GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lupin Ltd (BOM:500257) » Definitions » E10

Lupin (BOM:500257) E10 : ₹30.61 (As of Sep. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Lupin E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Lupin's adjusted earnings per share data for the three months ended in Sep. 2024 was ₹18.640. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹30.61 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Lupin's average E10 Growth Rate was -4.30% per year. During the past 3 years, the average E10 Growth Rate was -10.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Lupin was -10.20% per year. The lowest was -11.10% per year. And the median was -10.65% per year.

As of today (2024-12-16), Lupin's current stock price is ₹2075.55. Lupin's E10 for the quarter that ended in Sep. 2024 was ₹30.61. Lupin's Shiller PE Ratio of today is 67.81.

During the past 13 years, the highest Shiller PE Ratio of Lupin was 73.74. The lowest was 11.93. And the median was 23.21.


Lupin E10 Historical Data

The historical data trend for Lupin's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lupin E10 Chart

Lupin Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.51 42.22 34.19 31.94 30.61

Lupin Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.98 31.86 30.61 30.61 30.61

Competitive Comparison of Lupin's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Lupin's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lupin's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lupin's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Lupin's Shiller PE Ratio falls into.



Lupin E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Lupin's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=18.64/157.8822*157.8822
=18.640

Current CPI (Sep. 2024) = 157.8822.

Lupin Quarterly Data

per share eps CPI Adj_EPS
201412 13.330 96.780 21.746
201503 12.070 97.163 19.613
201506 12.570 99.841 19.877
201509 9.270 101.753 14.383
201512 11.590 102.901 17.783
201603 16.520 102.518 25.441
201606 19.470 105.961 29.010
201609 14.620 105.961 21.784
201612 13.980 105.196 20.982
201703 8.390 105.196 12.592
201706 7.890 107.109 11.630
201709 10.040 109.021 14.540
201712 4.890 109.404 7.057
201803 -17.330 109.786 -24.922
201806 4.480 111.317 6.354
201809 5.860 115.142 8.035
201812 -3.360 115.142 -4.607
201903 6.380 118.202 8.522
201906 6.670 120.880 8.712
201909 -2.810 123.175 -3.602
201912 -18.450 126.235 -23.075
202003 8.610 124.705 10.901
202006 2.350 127.000 2.921
202009 4.640 130.118 5.630
202012 9.630 130.889 11.616
202103 10.110 131.771 12.113
202106 11.910 134.084 14.024
202109 -46.220 135.847 -53.717
202112 11.980 138.161 13.690
202203 -11.400 138.822 -12.965
202206 -1.960 142.347 -2.174
202209 2.850 144.661 3.110
202212 3.360 145.763 3.639
202303 5.160 146.865 5.547
202306 9.900 150.280 10.401
202309 10.720 151.492 11.172
202312 13.410 152.924 13.845
202403 7.850 153.035 8.099
202406 17.520 155.789 17.755
202409 18.640 157.882 18.640

Add all the adjusted EPS together and divide 10 will get our e10.


Lupin  (BOM:500257) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Lupin's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=2075.55/30.61
=67.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Lupin was 73.74. The lowest was 11.93. And the median was 23.21.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Lupin E10 Related Terms

Thank you for viewing the detailed overview of Lupin's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Lupin Business Description

Traded in Other Exchanges
Address
Off. Western Express Highway, 3rd floor, Kalpataru Inspire, Santacruz (East), Mumbai, MH, IND, 400055
Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.

Lupin Headlines

No Headlines